https://orcid.org/0000-0003-0285-7449
Figures & data
Figure 1. Co-administration of miR-218-5p improves the efficacy of the chemotherapeutic drug DXR in stem and non-stem breast cancer cells. DXR treatment induces production of ROS and the mitophagic pathway mediated by PINK1 and PARKIN in BC cells. miR-218-5p, by inhibiting this mitophagy through PARKIN depletion, favours cytotoxicity of DXR. Created with BioRender.com.
